A retrospective study pooled 9 studies of PD-1/PD-L1 inhibitors containing 384 soft tissue sarcoma patients, of whom 153 (39.8%) received either a PD1 or PD-L1 inhibitor as a single agent. This evidence concerns the gene CD274 and soft tissue sarcoma.